Drug Trial Radar · NCT03644485
Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients
Last checked: Nov 20, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
284
Actual
Start
Oct 21, 2018
Primary completion
Jul 15, 2022
Study completion Jul 15, 2022
Sponsor
- Lead sponsor
- Astellas Pharma China, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Aug 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to confirm non-inferiority of delayed Prograf treatment to standard Prograf treatment in the incidence of delayed graft function (DGF) within 1 week between the 2 immunosuppressive (IS) treatment groups: delayed or standard Prograf together with induction therapy, and then convert to Advagraf usage in donation after cardiac (or circulatory) death (DCD) kidney transplant recipients. This study will also compare the clinical outcome within 6 month post-transplant between the 2 IS treatment groups and compare the safety throughout study period between the 2 IS treatment groups.
Conditions
- Kidney Transplant
Interventions
Tacrolimus immediate-release formulationDrug
oral
Tacrolimus prolonged-release formulationDrug
oral
Induction therapyDrug
All participants will receive induction therapy. The dosage and administration of induction immunotherapy will be a single kind of drug determined by the investigator.
Mycophenolic acid drugsDrug
All participants will receive mycophenolic acid drugs in combination with corticosteroids. The dosage and administration of mycophenolic acid will be determined by the investigator.
CorticosteroidsDrug
All participants will receive corticosteroids in combination with mycophenolic acid drugs. The dosage and administration of corticosteroids will be determined by the investigator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of delayed graft function (DGF)Time frame: Up to Day 7 after transplantation
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Site CN08608
Beijing, China
Site CN08619
Beijing, China
Site CN08609
Changsha, China
Site CN08604
Guangzhou, China
Site CN08614
Hangzhou, China
Site CN08617
Hangzhou, China
Site CN08610
Nanjing, China
Site CN08618
Nanjing, China
Site CN08612
Shanghai, China
Site CN08603
Tianjin, China
Site CN08621
Wenzhou, China
Site CN08602
Wuhan, China
Site CN08613
Wuhan, China
Site CN08605
Xi'an, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.